Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NMS-03305293 |
| Synonyms | |
| Therapy Description |
NMS-03305293 inhibits PARP1, potentially leading to decreased DNA damage repair, increased tumor cell apoptosis, and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NMS-03305293 | NMS03305293|NMS 03305293|NMS-293|NMS293|NMS 293 | PARP-1 Inhibitor 13 | NMS-03305293 inhibits PARP1, potentially leading to decreased DNA damage repair, increased tumor cell apoptosis, and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Terminated | USA | ITA | GBR | BGR | 1 |